Phase 1 and Phase 2 Clinical Trials Investigating Targets Against the Molecular Hallmarks of Gastroenteropancreatic Neuroendocrine Tumors

#992

Introduction: Recently there have been many advances in the diagnosis and treatment of gastroenteropancreatic neuroendocrine tumors (GEP NETs), accompanied by significant improvements in our understanding of GEP NET biology. A number of well-established or novel molecular hallmarks are involved in GEP NET tumorigenesis and may help in identifying potential diagnostic or therapeutic targets.

Aim(s): To characterize the current state-of-the-art of GEP NET clinical research, which may inform future patient care.

Materials and methods: We reviewed the current Phase 1 and Phase 2 clinical trials that investigate targets against GEP NET molecular hallmarks (www.clinicaltrials.gov).

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Tamagno G

Authors: Tamagno G, Crespo G, Fierro Maya F, Fossmark R, Igaz P,

Keywords: neuroendocrine tumor, clinical trial, hallmark,